FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895060287> ?p ?o ?g. }

• W2895060287 endingPage "1555" @default.
• W2895060287 startingPage "1549" @default.
• W2895060287 abstract "Abstract: Introduction: The effectiveness of the manegement of stable coronary artery disease among outpatients is not well known. Aim: The aim of the study was to evaluate the effect of daily once trimetazidine prolong 80 mg on the angina number and severity (Canadian Cardiovascular Society class). Method: This multicenter, prospective, observational, 3-month clinical study included 2160 patients, but only 1701 patients completed the study. The patients’ mean age was 68 years (17% under 60 years). The start of angina was 7.8 ± 6.7 years. Hypertension (93.4%) and hypercholesterolemia (81%) were very common. Results: The patients were well treated with beta-blocking agents (88%), calcium antagonists (49%), angiotensin-converting enzym inhibitors (90%) and statin (77%) but only 5% received ivabradine and 50.5% was treated with trimetazidine MR. The patients attended 3 visits (inclusion, 1 month, 3 month). During the 3-month period, the weekly angina number of all patients treated with trimetazidine prolong 80 mg decreased from 2.55 to 0.41 (p<0.0001). A favorable effect was observed in CCS grading: CCS I. from 40.37% to 66.81%, CCS II. from 49.89% to 30.59%, CCS III. from 9.17% to 2% and CCS IV. from 0.56% to 0%. The mean office measured blood pressure decreased from 137/83 mmHg to 130/80 mmHg and the heart rate from 74 bpm to 71 bpm. Conclusions: In the real-life, in the stable coronary artery disease the angina remains despite the medical treatment. Once a day administered trimetazidine prolong 80 mg significantly reduced the weekly number of angina and the severity, too. These beneficial effects mediated not only by antiischemic effect but also by increased medication adherence. Orv Hetil. 2018; 159(38): 1549–1555." @default.
• W2895060287 created "2018-10-12" @default.
• W2895060287 creator A5041057561 @default.
• W2895060287 creator A5046931969 @default.
• W2895060287 date "2018-09-01" @default.
• W2895060287 modified "2023-10-17" @default.
• W2895060287 title "Stabil coronariabetegség kezelésére alkalmazott trimetazidin prolong hatásosságának vizsgálata. <i>Multicentrikus, prospektív, obszervációs, nyílt klinikai vizsgálat, ONECAPS-vizsgálat</i>" @default.
• W2895060287 cites W1936833235 @default.
• W2895060287 cites W2004689814 @default.
• W2895060287 cites W2005094638 @default.
• W2895060287 cites W2005748654 @default.
• W2895060287 cites W2034882335 @default.
• W2895060287 cites W2107273587 @default.
• W2895060287 cites W2140337836 @default.
• W2895060287 cites W2141289234 @default.
• W2895060287 cites W2146561080 @default.
• W2895060287 cites W2317683134 @default.
• W2895060287 cites W2443840288 @default.
• W2895060287 cites W2512050464 @default.
• W2895060287 cites W2550573619 @default.
• W2895060287 doi "https://doi.org/10.1556/650.2018.31251" @default.
• W2895060287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30227735" @default.
• W2895060287 hasPublicationYear "2018" @default.
• W2895060287 type Work @default.
• W2895060287 sameAs 2895060287 @default.
• W2895060287 citedByCount "4" @default.
• W2895060287 countsByYear W28950602872020 @default.
• W2895060287 countsByYear W28950602872021 @default.
• W2895060287 countsByYear W28950602872022 @default.
• W2895060287 crossrefType "journal-article" @default.
• W2895060287 hasAuthorship W2895060287A5041057561 @default.
• W2895060287 hasAuthorship W2895060287A5046931969 @default.
• W2895060287 hasBestOaLocation W28950602872 @default.
• W2895060287 hasConcept C126322002 @default.
• W2895060287 hasConcept C164705383 @default.
• W2895060287 hasConcept C2777927741 @default.
• W2895060287 hasConcept C2778213512 @default.
• W2895060287 hasConcept C2778425758 @default.
• W2895060287 hasConcept C500558357 @default.
• W2895060287 hasConcept C71924100 @default.
• W2895060287 hasConcept C84393581 @default.
• W2895060287 hasConceptScore W2895060287C126322002 @default.
• W2895060287 hasConceptScore W2895060287C164705383 @default.
• W2895060287 hasConceptScore W2895060287C2777927741 @default.
• W2895060287 hasConceptScore W2895060287C2778213512 @default.
• W2895060287 hasConceptScore W2895060287C2778425758 @default.
• W2895060287 hasConceptScore W2895060287C500558357 @default.
• W2895060287 hasConceptScore W2895060287C71924100 @default.
• W2895060287 hasConceptScore W2895060287C84393581 @default.
• W2895060287 hasIssue "38" @default.
• W2895060287 hasLocation W28950602871 @default.
• W2895060287 hasLocation W28950602872 @default.
• W2895060287 hasLocation W28950602873 @default.
• W2895060287 hasOpenAccess W2895060287 @default.
• W2895060287 hasPrimaryLocation W28950602871 @default.
• W2895060287 hasRelatedWork W1971345608 @default.
• W2895060287 hasRelatedWork W2006624500 @default.
• W2895060287 hasRelatedWork W2030354228 @default.
• W2895060287 hasRelatedWork W2037371875 @default.
• W2895060287 hasRelatedWork W2077638279 @default.
• W2895060287 hasRelatedWork W2410513801 @default.
• W2895060287 hasRelatedWork W2760208121 @default.
• W2895060287 hasRelatedWork W3033271856 @default.
• W2895060287 hasRelatedWork W3141700921 @default.
• W2895060287 hasRelatedWork W4312186513 @default.
• W2895060287 hasVolume "159" @default.
• W2895060287 isParatext "false" @default.
• W2895060287 isRetracted "false" @default.
• W2895060287 magId "2895060287" @default.
• W2895060287 workType "article" @default.